LOADING

Type to search

Oncology Supporting Your Practice

Clinical Practice Guideline: Medication-Related Osteonecrosis of the Jaw (MRONJ)

This information is provided by the American Society of Clinical Oncology: Medication-Related Osteonecrosis of the Jaw

Guideline Question

What are the recommended best practices for preventing and managing medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer?

Target Population

Adult patients with cancer who are receiving bone-modifying agents (BMAs) for any oncologic indication.

Target Audience

Oncologists and other physicians, dentists, dental specialists, oncology nurses, clinical researchers, oncology pharmacists, advanced practitioners, and patients with cancer.

Methods

A systematic review of the medical literature was conducted and a multidisciplinary Expert Panel was convened to evaluate the evidence and develop recommendations. Given the low volume of high-quality evidence, a majority of the recommendations are based on consensus using ASCO’s formal consensus process.

Recommendations

Additional Resources

Leave a Comment

Your email address will not be published. Required fields are marked *